CLSA Statement on House Resolution 1425

Washington, DC (June 29, 2020) — California Life Sciences Association president and CEO Mike Guerra issued the following statement about the scheduled vote on H.R. 1425, the Patient Protection and Affordable Care Enhancement Act.

“CLSA supports increasing access to healthcare and has always advocated for common sense measures to achieve that goal. California’s life sciences innovators are working around the clock to combat the COVID-19 pandemic – while simultaneously researching and developing treatments that provide hope to patients and families battling other diseases. The last thing we should be doing is passing legislation that reduces innovation, threatens jobs, and weakens our ability to fight the next pandemic.

We are very concerned and disappointed by the addition of H.R. 3 provisions into H.R. 1425.

In 2019 CLSA commissioned a study from international health economics experts Vital Transformation and released the results alongside our trade partners that examines the impact of H.R.3 on California’s innovative biotechnology sector.

The analysis conclusively shows that implementing foreign price controls has negative effects on the entire U.S. biopharmaceutical ecosystem – and more specifically, that the number of new medicines developed by small and emerging California-based companies would have shrunk by 88 percent in the prior decade if H.R. 3 had been law.  That is an unacceptable impact to patients when legislation slashes the prospects of developing promising new treatments and medicines from 25 down to 3 and erodes the very hope for patients that the ACA is supposed to enshrine.

The study also estimates that enactment of H.R. 3 would result in the loss of at least 80,000 biopharmaceutical sector jobs nationwide.  Threatening high paying, essential jobs during the current economic downturn concerns us greatly since California is home to roughly 30 percent of the U.S. biopharmaceutical workforce.

Americans want healthcare to be less expensive, but also want it to be the most innovative in the world. The key to simultaneously achieving both of these goals is good public policy, and this legislation misses the mark. We simply cannot afford to short-circuit life-saving innovation.

On behalf of California’s life sciences innovators, a sector with more than 3,400 firms employing almost 1 million Californians, CLSA stands ready to work with Congress to find solutions that support our continued leadership in life sciences innovation and meaningfully delivers affordable, accessible, and innovative therapies for patients and their families.”


About California Life Sciences Association (CLSA)

California Life Sciences Association (CLSA) is the state’s largest and most influential life sciences advocacy and business leadership organization. With offices in Sacramento, San Diego, South San Francisco, and Washington DC, CLSA works closely with industry, government, academia and others to shape public policy, improve access to innovative technologies and grow California’s life sciences economy. CLSA serves biotechnology, pharmaceutical, medical device and diagnostics companies, research universities and institutes, investors and service providers throughout the Golden State.

Visit CLSA at, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.

Media Contact:
California Life Sciences Association (CLSA)
Oliver Rocroi | Vice President, Communications and External Affairs | 916-588-0965